drugset / Trial / NCT03339882

Remifemin Preventing the Climacteric Symptoms in Breast Cancer

NCT03339882

Phase 2 Completed 85 enrolled Zhejiang Cancer Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

LHRH-a is an important hormone treatment in breast cancer especially in high-risk hormone receptor-positive patients or hormone receptor-negative but needing ovarian function protecting. The climacteric symptoms caused by LHRH-a are often and prominent, which is a common clinical problem.

Timeline

Start
2017-01-04
Primary completion
2017-11-27
Completion
2018-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Black Cohosh Traditional medicine (herbal / TCM) 0.2 g Oral

Indications

No indication recorded.